JP2010024209A - External preparation for skin - Google Patents

External preparation for skin Download PDF

Info

Publication number
JP2010024209A
JP2010024209A JP2008190362A JP2008190362A JP2010024209A JP 2010024209 A JP2010024209 A JP 2010024209A JP 2008190362 A JP2008190362 A JP 2008190362A JP 2008190362 A JP2008190362 A JP 2008190362A JP 2010024209 A JP2010024209 A JP 2010024209A
Authority
JP
Japan
Prior art keywords
extract
skin
seeds
stem cells
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008190362A
Other languages
Japanese (ja)
Other versions
JP5123092B2 (en
Inventor
Koki Mori
好希 毛利
Yasushi Hasegawa
靖司 長谷川
Tsutomu Sakaida
勉 坂井田
Satoru Nakada
悟 中田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Menard Cosmetic Co Ltd
Original Assignee
Nippon Menard Cosmetic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Menard Cosmetic Co Ltd filed Critical Nippon Menard Cosmetic Co Ltd
Priority to JP2008190362A priority Critical patent/JP5123092B2/en
Publication of JP2010024209A publication Critical patent/JP2010024209A/en
Application granted granted Critical
Publication of JP5123092B2 publication Critical patent/JP5123092B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an external preparation for skin containing a material having excellent proliferation effect of stem cells existing in the skin and differentiation induction promoting effect to fibroblast and keratinocyte, effective for ameliorating roughened skin and wrinkle and comprehensively ameliorating skin damages caused by aging, etc. <P>SOLUTION: It has been found that extract of Prunus avium seed, extract of Hordeum vulgare seed and extract of Sterculia scaphigera seed respectively have excellent stem cell proliferation promoting effect, differentiation induction promoting effect to fibroblast and differentiation induction promoting effect to keratinocyte, and that an external preparation for skin containing these extracts has excellent effect for ameliorating roughened skin and wrinkle. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

本発明は、バラ科サクラ属に属するセイヨウミザクラ(学名:Prunus avium L.)の種子の抽出物を含有することを特徴とする皮膚内に存在する幹細胞の増殖促進用外用剤、イネ科オオムギ属に属する紫麦(学名:Hordeum vulgare L.)の種子の抽出物を含有することを特徴とする皮膚内に存在する幹細胞の線維芽細胞への分化誘導促進用外用剤、アオギリ科に属するハンタイカイ(学名:Sterculia scaphigera WALL)の種子の抽出物を含有することを特徴とする皮膚内に存在する幹細胞の角化細胞への分化誘導促進用外用剤及びこれらを含有することを特徴とする皮膚外用剤に関する。
The present invention relates to an external preparation for the growth promotion of stem cells present in the skin, which is characterized by containing an extract of seeds of Prunus avium L. belonging to the genus Rosaceae. An external preparation for promoting differentiation of stem cells existing in the skin into fibroblasts, comprising a seed extract of purple wheat (scientific name: Hordeum vulgare L.) belonging to the genus (Scientific name: Starcaria scaphigera WALL) seed extract characterized by containing an extract for promoting differentiation induction of stem cells existing in the skin into keratinocytes, and topical use for skin containing these It relates to the agent.

脊椎動物、特に哺乳動物の組織は、傷害もしくは疾患、又は加齢などに伴い細胞・臓器の損傷が起こった場合、再生系が働き、細胞・臓器の損傷を回復しようとする。この作用に、当該組織に備わる幹細胞が大きな役割を果たしている。幹細胞は、あらゆる細胞・臓器に分化する多能性を有しており、この性質により細胞・組織の損傷部を補うことで回復に導くと考えられている。このような幹細胞を応用した、次世代の医療である再生医療に期待が集まっている。
In the case of vertebrate, particularly mammalian tissue, when cell or organ damage occurs due to injury or disease, or aging, the regeneration system works to try to recover the damage of the cell or organ. Stem cells provided in the tissue play a major role in this effect. Stem cells have the pluripotency to differentiate into all cells and organs, and this property is thought to lead to recovery by compensating for damaged parts of cells and tissues. Expectations are gathered for regenerative medicine, which is the next generation of medicine using such stem cells.

哺乳動物における幹細胞研究で最も進んでいる組織は骨髄である。骨髄には生体の造血幹細胞が存在しており、すべての血液細胞再生の源であることが明らかにされた。さらに骨髄には、造血幹細胞とは別に、その他の臓器(例えば、骨、軟骨、筋肉、脂肪など)へ分化可能な幹細胞が包含されていることが報告されている(非特許文献1参照)。
さらに、近年、骨髄以外にも、肝臓、膵臓、脂肪、皮膚など、あらゆる臓器・組織に幹細胞が存在することが明らかにされ、各臓器・組織の再生および恒常性維持を司っていることがわかってきた(非特許文献2〜5参照)。
Pittenger M. F., et al., Science,1999,284,143−147 Goodell M. F., et al., Nat. Med., 1997,3,1337−1345 Zulewski H., et al., Diabetes, 2001,50,521−533 Suzuki A., et al., Hepatology, 2000,32,1230−1239 Zuk P. A., et al., Tissue Engineering, 2001,7,211−228
The most advanced tissue in stem cell research in mammals is the bone marrow. Bone marrow contains living hematopoietic stem cells, which have been shown to be the source of all blood cell regeneration. Furthermore, it has been reported that the bone marrow contains stem cells that can be differentiated into other organs (eg, bone, cartilage, muscle, fat, etc.) in addition to hematopoietic stem cells (see Non-Patent Document 1).
Furthermore, in recent years, it has been clarified that stem cells exist in all organs / tissues such as liver, pancreas, fat, skin, etc. in addition to bone marrow, and are responsible for the regeneration and homeostasis of each organ / tissue. It has been understood (see Non-Patent Documents 2 to 5).
Pittenger M.M. F. , Et al. , Science, 1999, 284, 143-147. Goodell M.M. F. , Et al. , Nat. Med. , 1997, 3, 1337-1345. Zulewski H. , Et al. , Diabetes, 2001, 50, 521-533 Suzuki A. , Et al. , Hepatology, 2000, 32, 1230-1239 Zuk P.M. A. , Et al. , Tissue Engineering, 2001, 7, 211-228.

幹細胞の存在する器官の中でも、皮膚は、紫外線などの刺激に日常的にさらされており、損傷が顕著に見られる器官である。
Among organs in which stem cells are present, skin is an organ that is routinely exposed to stimuli such as ultraviolet rays, and is significantly damaged.

皮膚内における幹細胞は、表皮及び真皮に存在していると考えられており(非特許文献6,7参照)、それらは多分化能を示し、皮膚の細胞にも分化可能であると考えられる(非特許文献8参照)。
Bickenbach Jr., et al., J. Invest. Dermatol., 1987,88,42−46 Chen FG., et al., J. Cell Sci.,2007,120,2875−2883 Fuchs E., et al., Dev. Cell, 2001, Jul.1(1),13−25, Review.
Stem cells in the skin are considered to be present in the epidermis and dermis (see Non-patent Documents 6 and 7), and they exhibit pluripotency and can be differentiated into skin cells ( Non-patent document 8).
Bickenbach Jr. , Et al. , J. et al. Invest. Dermatol. , 1987, 88, 42-46. Chen FG. , Et al. , J. et al. Cell Sci. , 2007, 120, 2875-2883. Fuchs E.M. , Et al. Dev. Cell, 2001, Jul. 1 (1), 13-25, Review.

しかしながら、現状では、幹細胞の有用性及び、皮膚への局在は示されているものの、幹細胞を増殖させ、表皮や真皮の細胞へと分化誘導することによって皮膚の損傷を回復させる素材についての検討はなされていない。
However, at present, the usefulness of stem cells and localization to the skin has been shown, but examination of materials that can restore skin damage by proliferating stem cells and inducing differentiation into epidermal and dermal cells. Has not been made.

また、本発明に用いるセイヨウミザクラ種子、紫麦種子及びハンタイカイ種子は、それぞれ単独で用いた皮膚外用剤は知られているが(特許文献1〜3参照)、組み合わせて用いることにより、効果を高めたものは検討されていない。
特開平11−315010 特開2008−143827 特開2005−194239
Further, for the cherry cherry seeds, purple wheat seeds and hantaikai seeds used in the present invention, external skin preparations used alone are known (see Patent Documents 1 to 3), but the effect can be obtained by using them in combination. The enhancements are not being considered.
JP 11-312010 A JP2008-143827 JP-A-2005-194239

かかる状況に鑑み、本発明は、皮膚における幹細胞を増殖させ、表皮や真皮の細胞に分化させる効果を持つ素材を提供し、それらを含有し、肌荒れやシワを改善し、皮膚の受ける損傷を総合的に改善することのできる皮膚外用剤を提供することを目的としている。
In view of such circumstances, the present invention provides a material having an effect of proliferating stem cells in the skin and differentiating into cells of the epidermis and dermis, containing them, improving rough skin and wrinkles, and comprehensively taking damage to the skin An object of the present invention is to provide an external preparation for skin that can be improved in an improved manner.

本発明者らは、上記課題の解決に向けて鋭意検討を行った結果、バラ科サクラ属に属するセイヨウミザクラ種子の抽出物の皮膚内に存在する幹細胞の優れた増殖促進効果、紫麦種子の抽出物の皮膚内に存在する幹細胞の優れた線維芽細胞への分化誘導促進効果及びハンタイカイ種子の抽出物の皮膚内に存在する幹細胞の角化細胞への優れた分化誘導促進効果を見出し、さらに、それらを含有した皮膚外用剤に、肌荒れやシワを改善する効果を確認し、本発明を完成するに至った。
As a result of intensive studies aimed at solving the above problems, the present inventors have found that the excellent proliferation promoting effect of stem cells existing in the skin of the extract of the cherry tree seed belonging to the Rosaceae genus Rosa, The effect of promoting the induction of differentiation of stem cells present in the skin into excellent fibroblasts and the effect of promoting the induction of differentiation of stem cells present in the skin of keratinocytes into keratinocytes, Furthermore, the effect of improving rough skin and wrinkles was confirmed in the external preparation for skin containing them, and the present invention was completed.

本発明は、即ち、以下の通りである。
(1)セイヨウミザクラ種子の抽出物を含有することを特徴とする、皮膚内に存在する幹細胞の増殖促進用外用剤。
(2)紫麦種子の抽出物を含有することを特徴とする、皮膚内に存在する幹細胞の線維芽細胞への分化誘導促進用外用剤。
(3)ハンタイカイ種子の抽出物を含有することを特徴とする、皮膚内に存在する幹細胞の角化細胞への分化誘導促進用外用剤。
(4)これらを含有することを特徴とする皮膚外用剤。
That is, the present invention is as follows.
(1) An external preparation for promoting proliferation of stem cells present in the skin, comprising an extract of cherry cherry seeds.
(2) An external preparation for promoting differentiation induction of stem cells present in the skin into fibroblasts, comprising an extract of purple wheat seeds.
(3) An external preparation for promoting differentiation induction of stem cells existing in the skin into keratinocytes, characterized by containing an extract of hantaikai seeds.
(4) A skin external preparation characterized by containing these.

以下、本発明をさらに詳細に説明する。
Hereinafter, the present invention will be described in more detail.

本発明に用いるセイヨウミザクラは、オウトウとも呼ばれ、学名はPrunus avium L.である。主要品種として、アメリカンチェリー、佐藤錦、ナポレオンなどの食用品種が挙げられる。紫麦は、頴、頴果、茎又は葉が紫色の大麦のことを指し、学名はHordeum vulgare L.である。例えば、大麦の品種ではOUC321、CI158、CI244等が挙げられる。ハンタイカイとは、アオギリ科に属する落葉高木で、学名はSterculia scaphigera WALLである。
The cherry tree cherry used in the present invention is also called sugar beet, and its scientific name is Prunus avium L. It is. The main varieties include edible varieties such as American Cherry, Nishiki Sato, and Napoleon. Purple barley refers to barley with purple straw, berries, stems or leaves, and the scientific name is Hordeum vulgare L. It is. For example, barley varieties include OUC321, CI158, CI244 and the like. Hanta Taikai is a deciduous tree belonging to the family Aogiri, and its scientific name is Sterculia scaphigera WALL.

上記植物からの抽出物の調製に際し、種子を含む植物体そのままを用いることも可能であり、花、葉、茎、根、樹皮又は果実などより選択した部位を混合して用いても良い。より好ましくは、種子のみを用いるのが良い。また、抽出には、植物体をそのまま使用しても良く、乾燥、粉砕、細切等の処理を行ってから抽出を行っても良い。
In preparing the extract from the plant, it is possible to use the plant body containing the seed as it is, and a portion selected from a flower, a leaf, a stem, a root, a bark or a fruit may be mixed and used. More preferably, only seeds are used. Moreover, a plant body may be used for extraction as it is, and you may extract after processing, such as drying, grinding | pulverization, and shredding.

抽出する溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン、流動パラフィン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル等)が挙げられる。好ましくは、水、低級アルコール及び液状多価アルコールが良く、特に好ましくは、水が良い。これらの溶媒は1種でも2種以上を混合して用いても良い。また、抽出法は特に限定されないが、加熱による抽出が好ましい。さらに上記抽出溶媒に酸やアルカリを添加してpH調整して用いてもよい。
Examples of the solvent to be extracted include water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohols (1,3-butylene glycol, propylene glycol). , Glycerin, etc.), ketones (acetone, methyl ethyl ketone, etc.), acetonitrile, esters (ethyl acetate, butyl acetate, etc.), hydrocarbons (hexane, heptane, liquid paraffin, etc.), ethers (ethyl ether, tetrahydrofuran, propyl ether) Etc.). Preferably, water, lower alcohol and liquid polyhydric alcohol are preferable, and water is particularly preferable. These solvents may be used alone or in combination of two or more. The extraction method is not particularly limited, but extraction by heating is preferable. Furthermore, the pH may be adjusted by adding an acid or alkali to the extraction solvent.

それぞれの種子の抽出物は、抽出した溶液のまま用いても良く、必要に応じて、濃縮、稀釈、濾過等の処理及び活性炭等による脱色、脱臭処理をして用いても良い。特に、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いることが好ましい。
Each seed extract may be used as it is, or may be used after treatment such as concentration, dilution, filtration, decolorization or deodorization with activated carbon or the like, if necessary. In particular, the extracted solution is preferably subjected to treatment such as concentration to dryness, spray drying, freeze drying, etc., and used as a dried product.

それぞれの種子の抽出物を溶液の状態で用いる場合の成分含有量は特に限定されないが、乾燥物として0.00001〜10重量%であることが好ましく、0.0001〜1重量%含まれる濃度で使用することが最も好ましい。0.00001重量%未満であると本発明の効果が十分に発揮されにくい場合がある。
The component content when each seed extract is used in the form of a solution is not particularly limited, but is preferably 0.00001 to 10% by weight as a dry product, and at a concentration of 0.0001 to 1% by weight. Most preferably it is used. If it is less than 0.00001% by weight, the effects of the present invention may not be sufficiently exerted.

また、本発明の皮膚外用剤は、効果を損なわない範囲内で、必要に応じ、通常の医薬品、医薬部外品、化粧品などに使用される成分を適宜配合することができる。例えば、油脂類、ロウ類、炭化水素類、脂肪酸類、アルコール類、エステル類、界面活性剤、pH調整剤、防腐剤、保湿剤、粉体、紫外線吸収剤、増粘剤、酸化防止剤、美白剤、キレート剤等の成分を配合することができる。
Moreover, the skin external preparation of this invention can mix | blend suitably the component used for a normal pharmaceutical, a quasi-drug, cosmetics, etc. as needed within the range which does not impair an effect. For example, fats and oils, waxes, hydrocarbons, fatty acids, alcohols, esters, surfactants, pH adjusters, preservatives, moisturizers, powders, UV absorbers, thickeners, antioxidants, Components such as a whitening agent and a chelating agent can be blended.

本発明の皮膚外用剤の用途は、特に限定されるものではないが、軟膏、乳剤、ゲル剤、ローション剤、クリーム剤、パップ剤、エアゾール剤、ペースト剤、プラスター剤、洗浄剤等に用いることができる。また、本発明の皮膚外用剤は医薬品、医薬部外品及び化粧品を含むものである。
The use of the external preparation for skin of the present invention is not particularly limited, but it is used for ointments, emulsions, gels, lotions, creams, poultices, aerosols, pastes, plasters, cleaning agents, etc. Can do. Moreover, the skin external preparation of this invention contains a pharmaceutical, a quasi-drug, and cosmetics.

本発明を詳細に説明するため、実施例を挙げるが、本発明はこれらに何ら限定されるものではない。
In order to describe the present invention in detail, examples will be given, but the present invention is not limited to these examples.

以下に、セイヨウミザクラ(ナポレオン)種子、紫麦種子、ハンタイカイ種子を用いた溶媒抽出物の製造例を示す。
Below, the manufacture example of the solvent extract using a cherry tree (Napoleon) seed, a purple wheat seed, and a Hantai Kai seed is shown.

製造例1 セイヨウミザクラ(ナポレオン)種子の熱水抽出物
セイヨウミザクラ種子の粉砕物25gに精製水500mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してセイヨウミザクラ種子の熱水抽出物を2.0g得た。
Production Example 1 Hot water extract of Japanese cherry (Napoleon) seeds 500 mL of purified water was added to 25 g of pulverized Japanese cherry seeds, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated. Lyophilized to obtain 2.0 g of a hot water extract of cherry cherry seeds.

製造例2 セイヨウミザクラ(ナポレオン)種子の50%エタノール抽出物
セイヨウミザクラ種子の粉砕物25gに50(v/v)%エタノール500mLを加え、常温で5日間抽出した後、濾過し、その濾液を濃縮乾固して、セイヨウミザクラ種子の50%エタノール抽出物を1.0g得た。
Production Example 2 50% ethanol extract of Japanese cherry (Napoleon) seeds 500 mL of 50 (v / v)% ethanol was added to 25 g of pulverized Japanese cherry seeds, extracted at room temperature for 5 days, filtered, and the filtrate. Was concentrated to dryness to obtain 1.0 g of a 50% ethanol extract of Japanese cherry seeds.

製造例3 セイヨウミザクラ(ナポレオン)種子のエタノール抽出物
セイヨウミザクラ種子の粉砕物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、セイヨウミザクラ種子のエタノール抽出物を3.3g得た。
Production Example 3 Ethanol extract of Japanese cherry (Napoleon) seeds 1 L of ethanol was added to 100 g of pulverized Japanese cherry seeds, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness. 3.3 g of ethanol extract of cherry seeds was obtained.

製造例4 紫麦種子の熱水抽出物
紫麦種子の粉砕物50gに精製水500mLを加え、95〜100℃で1時間抽出した後、濾過し、その濾液を濃縮乾固して、紫麦種子の熱水抽出物を9.2g得た。
Manufacture example 4 Hot water extract of purple wheat seeds 500 mL of purified water was added to 50 g of pulverized purple wheat seeds, extracted at 95-100 ° C. for 1 hour, filtered, and the filtrate was concentrated to dryness. 9.2 g of hot water extract of seeds was obtained.

製造例5 紫麦種子の50%エタノール抽出物
紫麦種子の粉砕物50gに50(v/v)%エタノール500mLを加え、常温で5日間抽出した後、濾過し、その濾液を濃縮乾固して、紫麦種子の50%エタノール抽出物を3.8g得た。
Production Example 5 50% Ethanol Extract of Purple Wheat Seed 500 g of 50 (v / v)% ethanol was added to 50 g of pulverized purple wheat seed, extracted at room temperature for 5 days, filtered, and the filtrate was concentrated to dryness. Thus, 3.8 g of a 50% ethanol extract of purple wheat seeds was obtained.

製造例6 紫麦種子のエタノール抽出物
紫麦種子の粉砕物50gにエタノール500mLを加え、常温で5日間抽出した後、濾過し、その濾液を濃縮乾固して、紫麦種子のエタノール抽出物を1.2g得た。
Production Example 6 Purple Wheat Seed Ethanol Extract 500 g of ethanol was added to 50 g of pulverized purple barley seed, extracted at room temperature for 5 days, filtered, and the filtrate was concentrated to dryness to obtain an ethanol extract of purple wheat seed. 1.2g was obtained.

製造例7 ハンタイカイ種子の熱水抽出物
ハンタイカイ種子の乾燥物20gに精製水800mLを加え、95〜100℃で2時間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してハンタイカイの熱水抽出物を3.4g得た。
Production Example 7 Hot water extract of hantaikai seeds 800 ml of purified water was added to 20 g of dried hantaikai seeds, extracted at 95-100 ° C. for 2 hours, filtered, and the filtrate was concentrated and freeze-dried. 3.4 g of water extract was obtained.

製造例8 ハンタイカイ種子の50%エタノール抽出物
ハンタイカイ種子の乾燥物20gに50(v/v)%エタノール400mLを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、ハンタイカイの50%エタノール抽出物を3.7g得た。
Production Example 8 50% ethanol extract of hantaikai seeds 400 ml of 50 (v / v)% ethanol was added to 20 g of dried kaitai seeds, extracted at room temperature for 7 days, filtered, and the filtrate was concentrated to dryness. 3.7 g of a 50% ethanol extract of hantaikai was obtained.

製造例9 ハンタイカイ種子のエタノール抽出物
ハンタイカイ種子の乾燥物100gにエタノール1Lを加え、常温で7日間抽出した後、濾過し、その濾液を濃縮乾固して、ハンタイカイのエタノール抽出物を6.7g得た。
Production Example 9 Hantaikai Seed Ethanol Extract 1 l of ethanol was added to 100 g of dried huntaikai seeds, extracted at room temperature for 7 days, filtered, the filtrate was concentrated to dryness, and 6.7 g of Hantaikai ethanol extract was obtained. Obtained.

次に、本発明に用いる種子の抽出物を用いた皮膚外用剤の処方例を挙げるが、本発明はこれに限定されるものではない。
Next, although the formulation example of the external preparation for skin using the seed extract used for this invention is given, this invention is not limited to this.

処方例1 軟膏
処方 配合量
1.セイヨウミザクラ種子の
50%エタノール抽出物(製造例2) 0.5部
2.紫麦種子の50%エタノール抽出物(製造例5) 0.5
3.ハンタイカイ種子の50%エタノール抽出物(製造例8)0.5
4.ポリオキシエチレンセチルエーテル(30E.O.) 2.0
5.モノステアリン酸グリセリン 10.0
6.流動パラフィン 5.0
7.セタノール 6.0
8.パラオキシ安息香酸メチル 0.1
9.プロピレングリコール 10.0
10.精製水にて全量を100とする
[製造方法]成分4〜7を加熱溶解して混合し、70℃に保ち油相とする。成分1〜3及び8〜10を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら30℃まで冷却して製品とする。
Formulation Example 1 Ointment Formulation Formulation 1. Of cherry seeds
50% ethanol extract (Production Example 2) 0.5 part 50% ethanol extract of purple wheat seeds (Production Example 5) 0.5
3. 50% ethanol extract of hantaikai seeds (Production Example 8) 0.5
4). Polyoxyethylene cetyl ether (30E.O.) 2.0
5). Glycerol monostearate 10.0
6). Liquid paraffin 5.0
7). Cetanol 6.0
8). Methyl paraoxybenzoate 0.1
9. Propylene glycol 10.0
10. [Manufacturing method] Components 4-7 are heated and dissolved and mixed with purified water to 100, and kept at 70 ° C to obtain an oil phase. Ingredients 1 to 3 and 8 to 10 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled to 30 ° C. with stirring to obtain a product.

比較例1〜4 従来の軟膏
処方例1において、セイヨウミザクラ種子の50%エタノール抽出物のみを含有したものを比較例1、紫麦種子の50%エタノール抽出物のみを含有したものを比較例2、ハンタイカイ種子の50%エタノール抽出物のみを含有したものを比較例3、すべて除いたものを比較例4とした。
Comparative Examples 1-4 Conventional Ointment In Formulation Example 1, Comparative Example 1 containing only 50% ethanol extract of Japanese cherry seeds Comparative Example Comparative Example containing only 50% ethanol extract of purple wheat seeds 2. A sample containing 50% ethanol extract of hantaikai seeds was used as Comparative Example 3, and a sample obtained by removing all of them was used as Comparative Example 4.

処方例2 乳剤
処方 配合量
1.セイヨウミザクラ種子の熱水抽出物(製造例1) 0.001部
2.紫麦種子の熱水抽出物(製造例4) 0.001
3.ハンタイカイ種子の熱水抽出物(製造例7) 0.001
4.スクワラン 5.0
5.オリーブ油 5.0
6.ホホバ油 5.0
7.セタノール 1.5
8.モノステアリン酸グリセリン 2.0
9.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
10.ポリオキシエチレンソルビタンモノオレエート
(20E.O.) 2.0
11.香料 0.1
12.プロピレングリコール 1.0
13.グリセリン 2.0
14.パラオキシ安息香酸メチル 0.2
15.精製水にて全量を100とする
[製造方法]成分4〜10を加熱溶解して混合し、70℃に保ち油相とする。成分1〜3及び12〜15を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分11を加え、更に30℃まで冷却して製品とする。
Formulation Example 2 Emulsion formulation Hot water extract of Japanese cherry seed (Production Example 1) 0.001 part Hot water extract of purple wheat seed (Production Example 4) 0.001
3. Hot water extract of hantaikai seeds (Production Example 7) 0.001
4). Squalane 5.0
5). Olive oil 5.0
6). Jojoba oil 5.0
7). Cetanol 1.5
8). Glycerol monostearate 2.0
9. Polyoxyethylene cetyl ether (20E.O.) 3.0
10. Polyoxyethylene sorbitan monooleate (20E.O.) 2.0
11. Fragrance 0.1
12 Propylene glycol 1.0
13. Glycerin 2.0
14 Methyl paraoxybenzoate 0.2
15. Make the total volume 100 with purified water
[Manufacturing method] Components 4 to 10 are heated and dissolved, mixed, and kept at 70 ° C to obtain an oil phase. Ingredients 1 to 3 and 12 to 15 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 11 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.

処方例3 ゲル剤
処方 配合量
1.セイヨウミザクラ種子のエタノール抽出物(製造例3) 1.0部
2.紫麦種子のエタノール抽出物(製造例6) 1.0
3.ハンタイカイ種子エキスのエタノール抽出物(製造例9)1.0
4.エタノール 5.0
5.パラオキシ安息香酸メチル 0.1
6.ポリオキシエチレン硬化ヒマシ油(60E.O.) 0.1
7.香料 適量
8.1,3−ブチレングリコール 5.0
9.グリセリン 5.0
10.キサンタンガム 0.1
11.カルボキシビニルポリマー 0.2
12.水酸化カリウム 0.2
13.精製水にて全量を100とする
[製造方法]成分4〜7と、成分1〜3及び8〜13をそれぞれ均一に溶解し、両者を混合して製品とする。
Formulation Example 3 Gel formulation Formulation amount 1. 1.0 parts of ethanol extract of cherry tree seeds (Production Example 3) Ethanol extract of purple wheat seeds (Production Example 6) 1.0
3. Ethanol extract of hantaikai seed extract (Production Example 9) 1.0
4). Ethanol 5.0
5). Methyl paraoxybenzoate 0.1
6). Polyoxyethylene hydrogenated castor oil (60 EO) 0.1
7). Perfume
8.1,3-Butylene glycol 5.0
9. Glycerin 5.0
10. Xanthan gum 0.1
11. Carboxyvinyl polymer 0.2
12 Potassium hydroxide 0.2
13. [Production method] Components 4 to 7 and components 1 to 3 and 8 to 13 are uniformly dissolved in purified water to a total amount of 100, and both are mixed to obtain a product.

処方例4 ローション剤
処方 配合量
1.セイヨウミザクラ種子の熱水抽出物(製造例1) 0.1部
2.紫麦種子の熱水抽出物(製造例4) 0.1
3.ハンタイカイ種子の熱水抽出物(製造例7) 0.1
4.1,3−ブチレングリコール 8.0
5.グリセリン 2.0
6.キサンタンガム 0.02
7.クエン酸 0.01
8.クエン酸ナトリウム 0.1
9.エタノール 5.0
10.パラオキシ安息香酸メチル 0.1
11.ポリオキシエチレン硬化ヒマシ油(40E.O.) 0.1
12.香料 適量
13.精製水にて全量を100とする
[製造方法]成分1〜8及び13と、成分9〜12をそれぞれ均一に溶解し、両者を混合し濾過して製品とする。
Formulation Example 4 Lotion preparation formulation Hot water extract of cherry tree seeds (Production Example 1) 0.1 part Hot water extract of purple wheat seeds (Production Example 4) 0.1
3. Hot water extract of hantaikai seed (Production Example 7) 0.1
4.1,3-Butylene glycol 8.0
5). Glycerin 2.0
6). Xanthan gum 0.02
7). Citric acid 0.01
8). Sodium citrate 0.1
9. Ethanol 5.0
10. Methyl paraoxybenzoate 0.1
11. Polyoxyethylene hydrogenated castor oil (40E.O.) 0.1
12 Perfume
13. [Manufacturing method] Components 1 to 8 and 13 and components 9 to 12 are uniformly dissolved in purified water, and the two are mixed and filtered to obtain a product.

処方例5 クリーム剤
処方 配合量
1.セイヨウミザクラ種子の
50%エタノール抽出物(製造例2) 0.05部
2.紫麦種子の50%エタノール抽出物(製造例5) 0.05
3.ハンタイカイ種子の50%エタノール抽出物(製造例8)0.05
4.スクワラン 5.5
5.オリーブ油 3.0
6.ステアリン酸 2.0
7.ミツロウ 2.0
8.ミリスチン酸オクチルドデシル 3.5
9.ポリオキシエチレンセチルエーテル(20E.O.) 3.0
10.ベヘニルアルコール 1.5
11.モノステアリン酸グリセリン 2.5
12.香料 0.1
13.パラオキシ安息香酸メチル 0.2
14.パラオキシ安息香酸エチル 0.05
15.1,3−ブチレングリコール 8.5
16.精製水にて全量を100とする
[製造方法]成分4〜11を加熱溶解して混合し、70℃に保ち油相とする。成分1〜3及び13〜16を加熱溶解して混合し、75℃に保ち水相とする。油相に水相を加えて乳化して、かき混ぜながら冷却し、45℃で成分12を加え、更に30℃まで冷却して製品とする。
Formulation Example 5 Cream formulation Formulation amount 1. Of cherry seeds
50% ethanol extract (Production Example 2) 0.05 part 50% ethanol extract of purple wheat seeds (Production Example 5) 0.05
3. 50% ethanol extract of hantaikai seeds (Production Example 8) 0.05
4). Squalane 5.5
5). Olive oil 3.0
6). Stearic acid 2.0
7). Beeswax 2.0
8). Octyldodecyl myristate 3.5
9. Polyoxyethylene cetyl ether (20E.O.) 3.0
10. Behenyl alcohol 1.5
11. Glycerol monostearate2.5
12 Fragrance 0.1
13. Methyl paraoxybenzoate 0.2
14 Ethyl paraoxybenzoate 0.05
15.1,3-Butylene glycol 8.5
16. [Manufacturing method] Components 4 to 11 are heated and dissolved and mixed with purified water to a total amount of 100, and kept at 70 ° C to obtain an oil phase. Ingredients 1 to 3 and 13 to 16 are dissolved by heating and mixed, and kept at 75 ° C. to obtain an aqueous phase. The aqueous phase is added to the oil phase to emulsify, and the mixture is cooled while stirring. The component 12 is added at 45 ° C., and further cooled to 30 ° C. to obtain a product.

以下に、実施例1で示した製造例1〜3のセイヨウミザクラ種子の抽出物を用いた、幹細胞の増殖促進効果の実験例とその結果を示す。
Below, the experiment example and result of the proliferation promotion effect of the stem cell using the cherry tree seed extract of the manufacture examples 1-3 shown in Example 1 are shown.

実験例1 幹細胞の増殖促進効果の評価
ヒト幹細胞培養液(TOYOBO社製)を用いて、ヒト体性幹細胞(DSファーマバイオメディカル社製)を6cmディッシュに1x10個播種し、セイヨウミザクラ種子の抽出物(製造例1〜3)を最終濃度が0.001%になるように添加し、3日間培養を続けた。次に細胞をPBS(−)にて3回洗浄した後、ラバーポリスマンにて集め、それぞれの細胞数をカウントした。
抽出物未添加時の総細胞数をコントロールとし、コントロールを100(%)とした場合の、セイヨウミザクラ種子の抽出物(製造例1〜3)添加時の細胞数の増減(%)を算出し、幹細胞の細胞増殖促進効果の評価を行った。
なお、本実験例では、一般的に幹細胞の増殖促進因子として使用されているStem Cell Factor(SCF:幹細胞成長因子)10ng/mL(Pepro Tech社製)を陽性コントロールとして設定し、比較対象とした。
Using Evaluation human stem cell culture growth promoting effect of Example 1 stem cells (TOYOBO Co. Ltd.) were seeded 1x10 5 cells Human somatic stem cells (DS Pharma manufactured by Biomedical) in 6cm dish, the sweet cherry seed Extracts (Production Examples 1 to 3) were added to a final concentration of 0.001%, and the culture was continued for 3 days. Next, the cells were washed three times with PBS (−) and then collected with a rubber policeman, and the number of each cell was counted.
Calculation of increase / decrease (%) in the number of cells when adding extracts of cherry cherry seeds (Production Examples 1 to 3) when the total number of cells when no extract is added is a control and the control is 100 (%) Then, the cell proliferation promoting effect of stem cells was evaluated.
In this experimental example, a stem cell factor (SCF: stem cell growth factor) 10 ng / mL (manufactured by Pepro Tech), which is generally used as a proliferation promoting factor for stem cells, was set as a positive control and used as a comparison target. .

これらの試験結果を表1に示した。その結果、セイヨウミザクラ種子の抽出物(製造例1〜3)全てに、顕著な幹細胞の細胞増殖促進効果が認められた。以上より、セイヨウミザクラ種子の抽出物の極めて優れた幹細胞の細胞増殖促進効果を明らかとし、セイヨウミザクラ種子の抽出物の増殖促進効果を確認した。これらセイヨウミザクラ種子の増殖効果は、現在、幹細胞の増殖促進因子として一般的に用いられているSCFに比べても、顕著に高い効果を示した。
なお、本実験例で用いた幹細胞以外にも、胚性の幹細胞(ES細胞)についても同様な試験を行ったところ、顕著な幹細胞の細胞増殖促進効果が認められた。
The test results are shown in Table 1. As a result, all the extracts of cherry cherry seeds (Production Examples 1 to 3) were found to have a remarkable effect of promoting stem cell proliferation. From the above, the extremely excellent stem cell growth promoting effect of the cherry tree seed extract was clarified, and the growth promoting effect of the cherry tree seed extract was confirmed. The proliferation effect of these cherry cherry seeds was significantly higher than that of SCF, which is currently generally used as a stem cell proliferation promoting factor.
In addition to the stem cells used in this experimental example, a similar test was performed on embryonic stem cells (ES cells), and a remarkable effect of promoting cell proliferation of stem cells was observed.

以下に、実施例1で示した製造例4〜6の紫麦種子の抽出物を用いた、幹細胞の線維芽細胞への分化誘導促進効果を評価し、該抽出物の幹細胞から線維芽細胞への分化誘導促進剤としての性能を確認する実験例とその結果を示す。
Below, the differentiation induction promotion effect to the fibroblast of the stem cell using the extract of the purple wheat seed of the manufacture examples 4-6 shown in Example 1 is evaluated, The stem cell to a fibroblast of this extract is evaluated. The experiment example which confirms the performance as a differentiation-induction promoter and the result are shown.

実験例2 幹細胞の線維芽細胞への分化誘導促進効果の評価
ヒト幹細胞培養液(TOYOBO社製)を用いて培養したヒト体性幹細胞(DSファーマバイオメディカル社製)を96wellプレートに5x10個播種し、紫麦の種子抽出物(製造例4〜6)を最終濃度が0.001%になるように添加して7日間培養を続けた。7日後、幹細胞から線維芽細胞への分化誘導効率について評価した。線維芽細胞への分化誘導効果の指標としては、1型コラーゲンの遺伝子発現(発現が高いほど線維芽細胞へ分化が促進した)を測定した。具体的には、細胞からTaqMan GENE Expression Cells−to−CtTMkit(アプライドバイオシステム社)を用いてmRNAを抽出し、リアルタイムPCRにより1型コラーゲンの遺伝子発現を測定した。
抽出物未添加時のコラーゲン遺伝子の発現をコントロール(100%)とした場合の、紫麦種子の抽出物(製造例4〜6)添加時のコラーゲン発現の増減(%)を算出し、幹細胞から線維芽細胞への分化誘導促進効果の評価を行った。
なお、本実験例では、一般的に線維芽細胞の分化誘導因子として使用されているbasic−Fibroblast Growth Factor(bFGF:線維芽細胞成長因子)10ng/mL(Pepro Tech社製)を陽性コントロールとして設定し、比較対象とした。
Experimental Example 2 Evaluation of the effect of promoting differentiation induction of stem cells into fibroblasts Seed 5x10 3 human somatic stem cells (DS Pharma Biomedical) cultured in human stem cell culture medium (manufactured by TOYOBO) on a 96-well plate. Then, purple wheat seed extract (Production Examples 4 to 6) was added to a final concentration of 0.001%, and the cultivation was continued for 7 days. Seven days later, the differentiation induction efficiency from stem cells to fibroblasts was evaluated. As an index of the effect of inducing differentiation into fibroblasts, type 1 collagen gene expression (the higher the expression, the more differentiated into fibroblasts) was measured. Specifically, mRNA was extracted from the cells using TaqMan GENE Expression Cells-to-Ct kit (Applied Biosystems), and the gene expression of type 1 collagen was measured by real-time PCR.
The increase / decrease (%) in collagen expression when the extract of purple wheat seeds (Production Examples 4 to 6) was added when the expression of the collagen gene when no extract was added was taken as a control (100%) was calculated from the stem cells. The effect of promoting differentiation induction into fibroblasts was evaluated.
In this experimental example, a basic-fibroblast growth factor (bFGF: fibroblast growth factor) 10 ng / mL (manufactured by Pepro Tech), which is generally used as a factor for inducing differentiation of fibroblasts, is set as a positive control. And it was set as a comparison target.

これらの試験結果を表2に示した。その結果、紫麦種子の抽出物(製造例4〜6)全てに、顕著な線維芽細胞への分化誘導促進効果が認められた。以上より、紫麦種子の抽出物に極めて優れた線維芽細胞への分化誘導促進効果を明らかとし、紫麦種子の抽出物の分化誘導促進剤としての効果を確認した。これら紫麦種子の抽出物の分化誘導促進効果は、現在、線維芽細胞の分化誘導因子として一般的に用いられているbFGFに比べても、顕著に高い効果を示した。
なお、本実験例で用いた幹細胞以外にも、胚性幹細胞(ES細胞)、その他、未分化な状態の細胞(体性幹細胞)についても試験を行ったところ、同様な効果が確認できた。
The test results are shown in Table 2. As a result, all the extracts of purple wheat seeds (Production Examples 4 to 6) showed a remarkable effect of promoting differentiation induction into fibroblasts. From the above, the effect of promoting differentiation induction into fibroblasts, which was extremely excellent for the extract of purple wheat seeds, was clarified, and the effect of the extract of purple wheat seeds as a differentiation induction promoter was confirmed. The effect of promoting differentiation induction of these purple wheat seed extracts was significantly higher than that of bFGF, which is currently generally used as a fibroblast differentiation inducer.
In addition to the stem cells used in the present experimental example, embryonic stem cells (ES cells) and other undifferentiated cells (somatic stem cells) were tested, and similar effects were confirmed.

以下に、実施例1で示した製造例7〜9のハンタイカイの種子抽出物を用いた、幹細胞の角化細胞への分化誘導促進効果を評価し、該抽出物の角化細胞への分化誘導促進剤としての効果について確認した。
Hereinafter, the effect of promoting the induction of differentiation of stem cells into keratinocytes using the seed extract of Hantaikai of Production Examples 7 to 9 shown in Example 1 is evaluated, and differentiation induction of the extract into keratinocytes is induced. The effect as an accelerator was confirmed.

実験例3 幹細胞の角化細胞への分化誘導促進効果の評価
MCDB153培養液(Sigma社製)に、ITS−Xサプリメント(100倍希釈、GIBCO社製)、ハイドロコルチゾン(0.4ng/mL、Sigma社製)、ペニシリン(100unit/mL、Sigma社製)とストレプトマイシン(100μg/mL、Sigma社製)を加えて調製した培地を用いて、マウス表皮組織から分離した幹細胞を、6cmディッシュに1x10個播種し、各抽出物(製造例7〜9)を最終濃度が0.001%になるように添加し、3日間培養を続けた。次に細胞をPBS(−)にて3回洗浄した後、ラバーポリスマンにて集め、血球計数板にて細胞数をカウントした後、CelLytic(Sigma社製)にてタンパク質を抽出し、角化細胞への分化状態の測定を豊岡らの報告に従って行った(非特許文献9参照)。
すなわち、角化細胞への分化状態を示しているインボルクリンタンパク質の発現量をウエスタンブロッティング法にて定量解析し、これを指標に、幹細胞から角化細胞への分化誘導促進効果を評価した。この場合、ハンタイカイの種子抽出物を添加せずに培養した細胞が発現したインボルクリンタンパク質の量をコントロール(100%)とし、各抽出物(製造例7〜9)を添加して培養した時のインボルクリンタンパク質の発現量を相対値(%)として算出し、コントロールと比較することで、角化細胞への分化誘導促進効果(%)について評価した。なお、本実験例では、一般的に角化細胞の分化誘導因子として使用されているEpidermal Growth Factor(EGF:角化細胞成長因子、非特許文献10参照)10ng/mL(Pepro Tech社製)を陽性コントロールとして設定し、比較対象とした。
豊岡 やよい,Molecular Medicinr臨時増刊号 再生医学,2003,106−115 Rheinwald.JD et al., Nature,1977,265,421−424
Experimental Example 3 Evaluation of stem cell keratinocyte differentiation induction promoting effect MCDB153 culture solution (manufactured by Sigma), ITS-X supplement (diluted 100 times, manufactured by GIBCO), hydrocortisone (0.4 ng / mL, Sigma) Co. Inc.), penicillin (100 unit / mL, Sigma) and streptomycin (100 [mu] g / mL, using a medium prepared by adding Sigma), stem cells isolated from mouse epidermal tissue, 1x10 6 cells in 6cm dishes After seeding, each extract (Production Examples 7 to 9) was added to a final concentration of 0.001%, and the culture was continued for 3 days. Next, the cells were washed three times with PBS (−), collected with a rubber policeman, counted with a hemocytometer, and then extracted with CelLytic (Sigma) to extract keratinocytes. The differentiation state was measured according to the report of Toyooka et al. (See Non-Patent Document 9).
That is, the expression level of involucrin protein showing the differentiation state into keratinocytes was quantitatively analyzed by Western blotting, and the differentiation induction promoting effect from stem cells to keratinocytes was evaluated using this as an index. In this case, the amount of involucrin protein expressed in cells cultured without adding the seed extract of Hantaikai was used as a control (100%), and the involucrin when each extract (Production Examples 7 to 9) was added and cultured. The expression level of the protein was calculated as a relative value (%), and compared with the control, the effect of promoting differentiation induction into keratinocytes (%) was evaluated. In this experimental example, Epidermal Growth Factor (EGF: keratinocyte growth factor, see Non-Patent Document 10) 10 ng / mL (manufactured by Pepro Tech), which is generally used as a differentiation inducing factor for keratinocytes, is used. It was set as a positive control and used for comparison.
Yayoi Toyooka, Extraordinary issue of Molecular Medicine, Regenerative Medicine, 2003, 106-115 Rheinwald. JD et al. , Nature, 1977, 265, 421-424.

これらの試験結果を表3に示した。その結果、ハンタイカイ種子の抽出物(製造例7〜9)全てに、顕著な幹細胞の角化細胞への分化誘導促進効果が認められた。以上より、ハンタイカイ種子の抽出物の極めて優れた幹細胞の角化細胞への分化誘導促進効果を明らかとし、ハンタイカイ種子の抽出物の分化誘導促進剤としての効果を確認した。これらハンタイカイの種子抽出物の分化誘導促進効果は、現在、角化細胞の分化誘導因子として一般的に用いられているEGFに比べても、顕著に高い効果を示した。
なお、本実験例で用いた幹細胞以外にも、胚性幹細胞(ES細胞)、その他、未分化な状態の細胞(体性幹細胞)についても試験を行ったところ、同様な効果が確認できた。
These test results are shown in Table 3. As a result, the remarkable effect of promoting the differentiation of stem cells into keratinocytes was observed in all the extracts of Hankaikai seeds (Production Examples 7 to 9). From the above, the effect of promoting the induction of differentiation of hantaikai seeds into keratinocytes was clarified, and the effect of the extract of hantaikai seeds as a differentiation induction promoter was confirmed. The effect of promoting the induction of differentiation of these hunting kai seed extracts was significantly higher than that of EGF, which is generally used as a differentiation-inducing factor for keratinocytes.
In addition to the stem cells used in the present experimental example, embryonic stem cells (ES cells) and other undifferentiated cells (somatic stem cells) were tested, and similar effects were confirmed.

実験例4 臨床試験
処方例1の軟膏を用いて肌荒れやシワが確認される女性25人(40〜60才)を対象に2ヶ月間の臨床試験を行った。25人をランダムに5人ずつ五群に分け、各群において、それぞれ、処方例1又は比較例1〜4の軟膏を使用してもらった。2ヶ月間の使用後、目視にて評価を行い、5(著効)〜0(効果なし)の6段階にスコア化し、各群の比較により評価した。
Experimental Example 4 Clinical Test A 25-month clinical test was conducted on 25 women (40 to 60 years old) with rough skin and wrinkles confirmed using the ointment of Formulation Example 1. Twenty-five people were randomly divided into five groups of five, and in each group, the ointment of Prescription Example 1 or Comparative Examples 1 to 4 was used. After use for 2 months, it was evaluated by visual observation, scored in 6 levels from 5 (effective) to 0 (no effect), and evaluated by comparing each group.

臨床試験の結果を表4に示した。処方例1の軟膏は比較例と比較して、有意に肌荒れやシワに対する改善効果を示した。なお、試験期間中、皮膚トラブルは一人もなく、安全性においても問題なかった。
The results of the clinical trial are shown in Table 4. The ointment of Formulation Example 1 significantly improved the effect on rough skin and wrinkles as compared with the comparative example. During the test period, there was no skin problem and there was no problem with safety.

処方例2〜5についても同様に臨床試験を行ったところ、いずれも安全で優れた肌荒れやシワに対する改善効果を示した。
A similar clinical test was conducted on Formulation Examples 2 to 5, and all showed safe and excellent improvement effects on rough skin and wrinkles.

本発明のセイヨウミザクラ種子の抽出物、紫麦種子の抽出物及びハンタイカイ種子の抽出物は、それぞれ皮膚内に存在する幹細胞の優れた増殖促進効果、線維芽細胞への分化誘導促進効果及び角化細胞への分化誘導促進効果を持ち、それらを含有した皮膚外用剤は、肌荒れやシワを改善する効果に優れており、医薬品や医薬部外品、化粧品として利用できる。   The extract of cherry cherry seed of the present invention, the extract of purple wheat seed, and the extract of hantaikai seed are excellent in promoting the proliferation of stem cells present in the skin, the effect of promoting differentiation induction into fibroblasts, and the horn, respectively. The skin external preparation containing them has an effect of promoting differentiation induction into keratinocytes, and is excellent in the effect of improving rough skin and wrinkles, and can be used as pharmaceuticals, quasi drugs, and cosmetics.

Claims (4)

セイヨウミザクラ種子の抽出物を含有することを特徴とする、皮膚内に存在する幹細胞の増殖促進用外用剤。
An external preparation for promoting the proliferation of stem cells present in the skin, comprising an extract of cherry prunus seeds.
紫麦種子の抽出物を含有することを特徴とする、皮膚内に存在する幹細胞の線維芽細胞への分化誘導促進用外用剤。
An external preparation for promoting differentiation induction of stem cells existing in the skin into fibroblasts, comprising an extract of purple wheat seeds.
ハンタイカイ種子の抽出物を含有することを特徴とする、皮膚内に存在する幹細胞の角化細胞への分化誘導促進用外用剤。
An external preparation for promoting differentiation induction of stem cells existing in the skin into keratinocytes, comprising an extract of hantaikai seeds.
セイヨウミザクラ種子の抽出物、紫麦種子の抽出物及びハンタイカイ種子の抽出物を含有することを特徴とする皮膚外用剤。
An external preparation for skin, comprising an extract of cherry cherry seeds, an extract of purple wheat seeds and an extract of hantaikai seeds.
JP2008190362A 2008-07-24 2008-07-24 Topical skin preparation Active JP5123092B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008190362A JP5123092B2 (en) 2008-07-24 2008-07-24 Topical skin preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008190362A JP5123092B2 (en) 2008-07-24 2008-07-24 Topical skin preparation

Publications (2)

Publication Number Publication Date
JP2010024209A true JP2010024209A (en) 2010-02-04
JP5123092B2 JP5123092B2 (en) 2013-01-16

Family

ID=41730353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008190362A Active JP5123092B2 (en) 2008-07-24 2008-07-24 Topical skin preparation

Country Status (1)

Country Link
JP (1) JP5123092B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012167048A (en) * 2011-02-14 2012-09-06 Nitto Best Kk Epidermal keratinization-normalizing agent
US20130108603A1 (en) * 2011-11-02 2013-05-02 Mark K. Bennett Collagen production compound
JP2013102752A (en) * 2011-11-16 2013-05-30 Nippon Menaade Keshohin Kk Melanocyte differentiation-inducing promotor and use method thereof
JP2016124797A (en) * 2014-12-26 2016-07-11 日本メナード化粧品株式会社 Periodontal tissue regeneration promoting agent
KR101796335B1 (en) 2010-06-01 2017-11-09 피아스 가부시키가이샤 Mesenchymal stem cell inducer, and method for induction of mesenchymal stem cell
JP2017222579A (en) * 2016-06-13 2017-12-21 日本メナード化粧品株式会社 Oral composition
JP2017226613A (en) * 2016-06-22 2017-12-28 日本メナード化粧品株式会社 Basic fibroblast growth factor production promoter

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820544A (en) * 1994-07-04 1996-01-23 Takasago Internatl Corp Reactive oxygen eliminator and food products and cosmetics formulated therewith
JP2000143437A (en) * 1998-11-09 2000-05-23 Ichimaru Pharcos Co Ltd Cosmetic composition containing huhectant vegetable extract
JP2000247829A (en) * 1999-02-24 2000-09-12 Mikimoto Pharmaceut Co Ltd Cosmetic, unregulated drug, medicine and food
JP2000319123A (en) * 1999-05-07 2000-11-21 Hisamitsu Pharmaceut Co Inc Sheet pack
JP2001213750A (en) * 2000-01-28 2001-08-07 Ichimaru Pharcos Co Ltd Cosmetic composition containing steam-distilled water of rosaceae plant
JP2005075811A (en) * 2003-09-03 2005-03-24 Shiseido Co Ltd Trypsin specific activity inhibitor
JP2005194239A (en) * 2004-01-08 2005-07-21 Nippon Menaade Keshohin Kk Ceramide synthesis promotor and skin care preparation for external use
JP2007008908A (en) * 2005-07-04 2007-01-18 Takahito Tokuyama Cell proliferation enhancer and cell-repairing agent using cereals except rice or pulse crops as raw material
JP2008100981A (en) * 2006-10-17 2008-05-01 Engelhard Lyon Sas USE OF SUBSTANCE FOR PROTECTING FGF-2 OR FGF-beta GROWTH FACTOR
JP2008143827A (en) * 2006-12-08 2008-06-26 Nippon Menaade Keshohin Kk Skin care preparation, skin-lightening agent and composition for internal use
JP2009232727A (en) * 2008-03-26 2009-10-15 Nippon Menaade Keshohin Kk Stem cell cultured by specific method and method for producing the same
JP2009232726A (en) * 2008-03-26 2009-10-15 Nippon Menaade Keshohin Kk Stem cell cultured by specific method and method for producing the same
JP2009232724A (en) * 2008-03-26 2009-10-15 Nippon Menaade Keshohin Kk Stem cell cultured by specific method and method for producing the same
JP2010022326A (en) * 2008-07-23 2010-02-04 Nippon Menaade Keshohin Kk Differentiation-induced fibroblast and artificial dermis from stem cell
JP2010022327A (en) * 2008-07-23 2010-02-04 Nippon Menaade Keshohin Kk Keratinocyte and artificial epidermis sheet differentiation-induced from stem cell

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820544A (en) * 1994-07-04 1996-01-23 Takasago Internatl Corp Reactive oxygen eliminator and food products and cosmetics formulated therewith
JP2000143437A (en) * 1998-11-09 2000-05-23 Ichimaru Pharcos Co Ltd Cosmetic composition containing huhectant vegetable extract
JP2000247829A (en) * 1999-02-24 2000-09-12 Mikimoto Pharmaceut Co Ltd Cosmetic, unregulated drug, medicine and food
JP2000319123A (en) * 1999-05-07 2000-11-21 Hisamitsu Pharmaceut Co Inc Sheet pack
JP2001213750A (en) * 2000-01-28 2001-08-07 Ichimaru Pharcos Co Ltd Cosmetic composition containing steam-distilled water of rosaceae plant
JP2005075811A (en) * 2003-09-03 2005-03-24 Shiseido Co Ltd Trypsin specific activity inhibitor
JP2005194239A (en) * 2004-01-08 2005-07-21 Nippon Menaade Keshohin Kk Ceramide synthesis promotor and skin care preparation for external use
JP2007008908A (en) * 2005-07-04 2007-01-18 Takahito Tokuyama Cell proliferation enhancer and cell-repairing agent using cereals except rice or pulse crops as raw material
JP2008100981A (en) * 2006-10-17 2008-05-01 Engelhard Lyon Sas USE OF SUBSTANCE FOR PROTECTING FGF-2 OR FGF-beta GROWTH FACTOR
JP2008143827A (en) * 2006-12-08 2008-06-26 Nippon Menaade Keshohin Kk Skin care preparation, skin-lightening agent and composition for internal use
JP2009232727A (en) * 2008-03-26 2009-10-15 Nippon Menaade Keshohin Kk Stem cell cultured by specific method and method for producing the same
JP2009232726A (en) * 2008-03-26 2009-10-15 Nippon Menaade Keshohin Kk Stem cell cultured by specific method and method for producing the same
JP2009232724A (en) * 2008-03-26 2009-10-15 Nippon Menaade Keshohin Kk Stem cell cultured by specific method and method for producing the same
JP2010022326A (en) * 2008-07-23 2010-02-04 Nippon Menaade Keshohin Kk Differentiation-induced fibroblast and artificial dermis from stem cell
JP2010022327A (en) * 2008-07-23 2010-02-04 Nippon Menaade Keshohin Kk Keratinocyte and artificial epidermis sheet differentiation-induced from stem cell

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101796335B1 (en) 2010-06-01 2017-11-09 피아스 가부시키가이샤 Mesenchymal stem cell inducer, and method for induction of mesenchymal stem cell
JP2012167048A (en) * 2011-02-14 2012-09-06 Nitto Best Kk Epidermal keratinization-normalizing agent
US20130108603A1 (en) * 2011-11-02 2013-05-02 Mark K. Bennett Collagen production compound
US8895034B2 (en) * 2011-11-02 2014-11-25 Mark K Bennett Collagen production compound
JP2013102752A (en) * 2011-11-16 2013-05-30 Nippon Menaade Keshohin Kk Melanocyte differentiation-inducing promotor and use method thereof
JP2016124797A (en) * 2014-12-26 2016-07-11 日本メナード化粧品株式会社 Periodontal tissue regeneration promoting agent
JP2017222579A (en) * 2016-06-13 2017-12-21 日本メナード化粧品株式会社 Oral composition
JP2017226613A (en) * 2016-06-22 2017-12-28 日本メナード化粧品株式会社 Basic fibroblast growth factor production promoter

Also Published As

Publication number Publication date
JP5123092B2 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
KR101894229B1 (en) Functional composition comprising deer antlers derived stem cell culture medium
KR101885501B1 (en) Functional composition comprising deer antlers derived stem cell culture medium
JP5123092B2 (en) Topical skin preparation
KR100853761B1 (en) Extract of Stewartia koreana and Use Thereof
CN108498408B (en) Whitening essence
TWI605830B (en) Antiaging cosmetic composition, method of enhancing skin elasticity, method of improving skin wrinkles, and method of increasing skin moisturing
JP2020193198A (en) Fermented extract of aerial parts of bitter orange
JP2011088845A (en) Involucrin expression inhibitor
EP3656850A1 (en) Mesenchymal-stem-cell induction agent
CN107970278B (en) Hydrolysate of water extract of wax apple, preparation method and application thereof
JP6671894B2 (en) External preparation for skin
FR2928549A1 (en) USE OF AN EXTRACT OF BRASSOCATTLEYA MARCELLA KOSS ORCHIDEE AS AN AGENT TO PREVENT OR DELAY THE APPEARANCE OF SIGNS OF SKIN AGING
KR20120053260A (en) Skin external composition containing morus bombycis extract, eclipta prostrata extract or hovenia dulcis fruit extract
JP2002284648A (en) Composition for hair restorer
KR101892641B1 (en) Skin External Composition Containing Ulmus Davidiana Extract, Dioscorea Japonica Extract or Morus Alba Leaf Extract
JP2011088854A (en) Involucrin expression inhibitor
TWI648054B (en) Hydrolysate of water extract of Asparagus officinalis, preparation method and use thereof
JP5247548B2 (en) Moisturizer, anti-aging agent, neutral fat accumulation inhibitor, whitening agent, anti-inflammatory agent, topical skin preparation, oral preparation
JP5383001B2 (en) Skin preparations, moisturizers, anti-aging agents, antioxidants, anti-inflammatory agents, whitening agents, and slimming agents
JP6847194B2 (en) Manufacturing method of external preparation for skin
JP7539134B2 (en) Agent for promoting differentiation of epidermal stem cells into epidermal keratinocytes
KR102500786B1 (en) Composition of skin external application for promoting skin volume or renewing
JP7433628B2 (en) Skin external preparations and internal preparations
KR102109829B1 (en) Cosmetic Composition
KR20110101727A (en) Composition for improving skin wrinkle

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110521

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121023

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121025

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151102

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5123092

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250